Form 4: NeuroPace Executive Reports Stock Transactions

NeuroPace Inc. Chief Medical Officer Martha Morrell reports transactions involving restricted stock units and stock options.

Summary

• Martha Morrell, Chief Medical Officer of NeuroPace Inc., has reported transactions related to her beneficial ownership of company securities.
• On May 15, 2026, Morrell acquired 5,460 shares of Common Stock.
• This acquisition of 5,460 shares is represented by restricted stock units (RSUs), where each RSU is a contingent right to receive one share of common stock upon settlement.
• Additionally, Morrell acquired a stock option (right to buy) for 14,550 shares of common stock at an exercise price of $15.36.
• Following these transactions, Morrell beneficially owns 52,743 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider stock transactions and compensation-related equity grants rather than significant strategic or financial performance indicators.

Positives

• Acquisition of 5,460 restricted stock units (RSUs) by the Chief Medical Officer, indicating continued equity participation.
• Acquisition of a stock option for 14,550 shares by the Chief Medical Officer, suggesting potential future equity gains.
• The Chief Medical Officer's total beneficial ownership remains substantial at 52,743 shares.

Future Outlook

The vesting schedules for the RSUs and stock options indicate future equity grants to the Chief Medical Officer, with initial vesting on May 15, 2027, and subsequent vesting over quarterly and monthly periods, respectively.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The acquisition of RSUs and stock options by a Chief Medical Officer is typical for executive compensation and aligns their interests with shareholders, particularly in the biotechnology and medical device sectors where NeuroPace operates.

Stakeholder Impact

• Shareholders: The transactions reflect executive compensation and potential future equity dilution, which is a standard consideration for investors.
• Employees: The vesting schedules for RSUs and options can influence employee morale and retention.
• Management: The grants align the Chief Medical Officer's incentives with the company's performance.

Next Steps

• Vesting of 25% of RSUs and stock options on May 15, 2027.
• Continued quarterly vesting of remaining RSUs and monthly vesting of remaining stock options thereafter.

Key Dates

Keywords

NeuroPace Inc., NPCE, Form 4, Martha Morrell, Chief Medical Officer, Stock Options, Restricted Stock Units, Beneficial Ownership, SEC Filing